Exhibit 99.1

PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update

Princeton, NJ, November 7, 2019
- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® today announced its financial results for the third quarter ended September 30, 2019.

Third Quarter 2019 and Recent Business Highlights


Reported promising Phase 1 clinical outcome data of PDS0101 in patients with cervical intraepithelial neoplasia (CIN) infected with multiple high-risk, cancer-causing types of human papillomavirus (HPV). The study demonstrated robust treatment-induced HPV16-specific killer T-cell (CD8+) responses as well as clearance of the disease and regression of lesions in 60% of evaluable patients;

Announced clinical collaboration with Merck to evaluate PDS0101 in combination with KEYTRUDA® (pembrolizumab) in first line treatment of metastatic head and neck cancer;

Completed manufacturing of clinical batches of PDS0101 for upcoming Phase 2 combination trials with Merck and National Cancer Institute; and

Entered into a common stock purchase agreement with Aspire Capital Fund, LLC, to purchase up to an aggregate of $20.0 million of the Company’s common stock.

“We are honored to partner with proven leaders in the field of immuno-oncology as we prepare to advance our lead candidate PDS0101 into multiple Phase 2 combination studies for various HPV-associated cancers,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotechnology. “We believe that our combination approach is supported by our recently announced Phase 1 clinical outcome data demonstrating not only lesion regression in 60% of evaluable patients, but also PDS0101’s unique ability to promote the in-vivo induction of high levels of CD8+ T-cells. By promoting the induction of these tumor-specific CD8+ killer T-cells, our Versamune® platform could be critical to expanding clinical efficacy of checkpoint inhibitors and potentially address unmet patient needs for improved treatment options across a range of advanced cancers.”

“In the first quarter of 2020, we anticipate initiating three studies including; a Phase 2combination study to evaluate PDS0101 in combination with KEYTRUDA® in the treatment of head and neck cancer, a Phase 2 study to evaluate PDS0101 in combination with two immunotherapies in advanced HPV associated cancers with the National Cancer Institute and a Phase 2a study to evaluate the combination of PDS0101 and chemoradiation in patients with locally advanced cervical cancer. We are working diligently to activate all three clinical programs and recently completed the manufacturing of clinical batches of PDS0101. The stock purchase agreement with Aspire also provides the Company with financial flexibility to support these trials,” concluded Dr. Bedu-Addo.

Third Quarter 2019 Financial Review

For the third quarter of 2019, net loss was approximately $(5.8) million, or $(1.10) per basic and diluted share, compared to a net loss of approximately $(0.7) million, or $(0.21) per basic and diluted share for the third quarter of 2018.


Research and development expenses totaled approximately $1.8 million for the third quarter of 2019, compared to approximately $0.2 million for the same period in 2018, an increase of 845%. The increase of $1.6 million in 2019 was primarily attributable to an increase in external expenses for clinical studies of $1.1 million and an increase of $0.5 million in personnel costs.

For the third quarter of 2019, general and administrative expenses were approximately $3.1 million compared with approximately $0.5 million for the third quarter of 2018, an increase of 494%. The increase of $2.6 million is primarily attributable to increases in personnel costs of $0.5 million, D&O insurance of $0.5 million, stock-based consulting fees of $0.6 million, professional fees of $0.2 million, legal fees of $0.4 million and other operating expenses of $0.4 million.

Total operating expenses for the third quarter of 2019 were approximately $5.8 million, compared to total operating expenses of approximately $0.7 million for the same period in 2018, an increase of 723%.

As of September 30, 2019, the Company’s cash balance was approximately $17.4 million.

About PDS Biotechnology

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immune-oncology company developing multiple therapies based on T-cell activating technology.  The company’s proprietary Versamune® platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, resulting in the production of antigen-specific T-cells.  Using Versamune®, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors.  PDS Biotechnology’s pipeline combines Versamune® technology with tumor-specific antigens across several cancer types.  To learn more, please visit www.pdsbiotech.com.

About PDS0101

PDS Biotechnology’s lead candidate, PDS0101, combines the utility of the Versamune® platform with a targeted antigen in HPV-expressing cancers.  In partnership with Merck and the National Cancer Institute (NCI), PDS Biotechnology is advancing PD0101 to Phase 2 studies in head and neck cancer and in HPV-related advanced cancer.


Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Company’s ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Company’s interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Tram Bui / Alexander Lobo
The Ruth Group
Phone: +1-646-536-7035 / +1-646-536-7037
Email: tbui@theruthgroup.com / alobo@theruthgroup.com

(Financial Statements to Follow)


PDS BIOTECHNOLOGY CORPORATION

Condensed Consolidated Balance Sheets


   
September 30, 2019
   
December 31, 2018
 
ASSETS
 
(unaudited)
       
Current assets:
           
Cash and cash equivalents
 
$
17,406,608
   
$
103,695
 
Prepaid expenses and other
   
726,959
     
156,628
 
Total current assets
   
18,133,567
     
260,323
 
                 
Property and equipment, net
   
26,929
     
29,508
 
Intangible assets, net
   
1,223,000
     
41,692
 
Other assets
   
     
12,800
 
                 
Total assets
 
$
19,383,496
   
$
344,323
 
                 
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
               
LIABILITIES
               
Current liabilities:
               
Accounts payable
 
$
1,488,961
   
$
1,412,951
 
Accrued expenses
   
1,296,606
     
601,889
 
Restructuring reserve
   
858,332
     
 
Total current liabilities
   
3,643,899
     
2,014,840
 
                 
Noncurrent liability:
               
Deferred tax liability
   
157,000
     
 
Convertible promissory notes payable
   
     
30,000
 
                 
STOCKHOLDERS' EQUITY (DEFICIT)
               
Preferred stock, 5,000,000  shares authorized at September 30, 2019 and December 31, 2018, 0 outstanding
   
     
 
Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2019 and December 31, 2018, 5,278,850 shares and 3,417,187 shares issued and outstanding at September 30, 2019 and  December 31, 2018, respectively
   
1,742
     
1,128
 
Additional paid-in capital
   
39,414,792
     
19,311,529
 
Accumulated deficit
   
(23,833,937
)
   
(21,013,174
)
Total stockholders' equity (deficit)
   
15,582,597
     
(1,700,517
)
                 
Total liabilities and stockholders' equity (deficit)
 
$
19,383,496
   
$
344,323
 


PDS BIOTECHNOLOGY CORPORATION

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

   
Three Months Ended September 30,
   
Nine Months Ended September 30,
 
   
2019
   
2018
   
2019
   
2018
 
Operating expenses:
                       
Research and development expenses
 
$
1,834,371
   
$
194,068
   
$
4,751,308
   
$
563,812
 
General and administrative expenses
   
3,068,581
     
516,202
     
9,358,429
     
1,450,429
 
Lease termination costs
   
944,445
     
     
944,445
     
 
                                 
Total operating expenses
   
5,847,397
     
710,270
     
15,054,182
     
2,014,241
 
                                 
Loss from operations
   
(5,847,397
)
   
(710,270
)
   
(15,054,182
)
   
(2,014,241
)
                                 
Other income (expense):
                               
Gain on bargain purchase upon merger
   
     
     
11,939,331
     
 
Interest income
   
95,787
     
4
     
294,694
     
14
 
Interest expense
   
     
(942
)
   
(606
)
   
(2,705
)
                                 
Net income (loss) and comprehensive income (loss)
   
(5,751,610
)
   
(711,208
)
   
(2,820,763
)
   
(2,016,932
)
                                 
Net income (loss) per share, basic and diluted
 
$
(1.10
)
 
$
(0.21
)
 
$
(0.60
)
 
$
(0.62
)
                                 
Weighted average common shares outstanding, basic and diluted
   
5,246,829
     
3,346,237
     
4,729,153
     
3,253,085
 




The following information was filed by Pds Biotechnology Corp (PDSB) on Thursday, November 7, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Pds Biotechnology Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pds Biotechnology Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account